Over the past decade, the management of aortic stenosis (AS) has transitioned from surgical to transcatheter interventions for all risk groups using the balloon- and self-expanding prostheses [1] . One of the upcoming transcatheter heart valves (THV) already utilized in Europe, but yet to come to the U.S., are the self-expanding ACURATE Neo and Neo2 (Boston Scientific, Natick, MA, U.S.) implants. The Neo2 is under clinical trial as part of the randomized REPRISE IV trial comparing this prosthesis to either of the commercially available balloon- or self-expanding THVs in all risk categories. Miyashita and colleagues [2] present data and insights from their single center contemporary transcatheter aortic valve replacement (TAVR) series comparing 449 patients undergoing the ACURATE Neo or Neo2 implants from 2016 to 2021 in Finland. They performed a propensity matching which resulted in 94 pairs for comparison. This represents patients considered low to intermediate risk with a mean Society of Thoracic Surgeons (STS) score of 3.4 % and an average age of 80–81 years of age. The authors noted excellent clinical outcomes with no short-term mortality and 90 % device success in the Neo2 patients and 88.3 % in the Neo group (p = 0.654). The authors demonstrate excellent rates of permanent pacemaker implantation (PPI) utilizing this self-expanding THV. Although there was a 50 % decrease in the rate of a new pacemaker implant in the Neo2 group (3.5 vs 7.1, p = 0.496), this was not statistically significant; most likely from the small sample size. When compared to other self-expanding THV devices, this is very favorable in the rate of PPI.